Protein Engineering Associate – Contract @ Palleon Pharmaceuticals, Waltham, MA

Job description:

Palleon Pharmaceuticals seeks a highly motivated and talented contract protein engineering associate to advance discovery research platforms and novel therapeutic programs. The qualified candidate will be a highly motivated, interactive, and creative individual that possesses substantial research experience in antibody discovery and engineering. The contract position will be up to six month in duration.

Protein Engineering Associate – Contract @ Palleon Pharmaceuticals, Waltham, MA

Title: Protein Engineering Associate- Contract

Location: Waltham, MA

Position Responsibilities:

  • Perform PCR amplification, cloning, mutagenesis, and vector construction
  • Conduct high throughput binding and activity screening
  • Express antibodies/proteins using mammalian cells in 24-well plates and shaking flasks
  • Purify antibodies/proteins using affinity and ion exchange chromatography
  • Characterize antibodies and proteins using Octet, ELISA, FACS, etc.

Requirements:

  • MS/BS degree in molecular biology, protein biochemistry or related field
  • Strong molecular biology skills
  • Experience in using AKTA purification system
  • Well-organized, self-directed and self-motivated with “can-do” and continuous learning attitude
  • Ability to work in a creative and fast-paced culture and productive team environment
  • Team player with strong interpersonal skills and high ethical standard

Who We Are:

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoints to treat cancer. The company’s proprietary CONVERGENCE and EAGLE platforms integrate technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glycoimmune Checkpoint inhibition will tackle resistance to first-generation immuno-oncology agents and make possible a wider range of rational combination therapies to treat cancer. Palleon has several cancer drug discovery programs underway. Beyond oncology, other important areas where Glyco-Immune Checkpoints may play a role include infectious diseases, neurodegeneration, inflammation, and fibrosis.  The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures. Learn more at www.palleonpharma.com.

View original advertisement

Leave a Reply